Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer

ConditionProstate Carcinoma

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexMale

Age35-70

SponsorUniversity of Michigan Rogel Cancer Center

About this trial

This study evaluates urinary biomarkers and PSA to help determine the best approach to early detection of prostate cancer in patients with an elevated familial risk.

Eligibility criteria

Qualifiers

* Age 35-70 years

Capable of providing informed consent

Prognosis of > 5 years if affected by another cancer

Known PCa-related mutations: BRCA 1 and 2, Lynch syndrome, or p53

Disqualifiers

* Anuria

Prior diagnosis or treatment for PCa

Failure to provide informed consent

Life expectancy < 5 years

Trial design

Treatments tested in this trial

Non-Interventional Study

Treatment groups

200 Participants

are divided into 1 treatment group

Locations

University of Michigan Rogel Cancer Center48109, Ann ArborMichigan, United States

Sponsors and collaborators

University of Michigan Rogel Cancer Center

Lead sponsor

National Cancer Institute (NCI)

Collaborator

Source ClinicalTrials.gov